Skip to main content
. 2014 Sep 22;25(10):1801–1810. doi: 10.1021/bc500312w

Figure 2.

Figure 2

(A) Absorption spectra of SE-HPLC-purified ICG-sOSu-panitumumab (1, 2, and 3) from 600 to 900 nm. (B) Competition radioimmunoassay of SE-HPLC-purified ICG-sOSu-panitumumab (1, 2, and 3) with 125I-panitumumab. ICG-sOSu-HuM195 and HuM195 served as negative controls while unmodified panitumumab served as a positive control.